ADVISORY, Nov. 20, 2017 (GLOBE NEWSWIRE) --
What: Spero Therapeutics, Inc. (Nasdaq: SPRO ), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, will visit the Nasdaq MarketSite in Times Square in celebration of its recent IPO.
In honor of the occasion, Ankit Mahadevia, MD, President and CEO , will ring the Closing Bell.
Where: Nasdaq MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio
When: Tuesday, November 21, 2017 – 3:45 p.m. to 4:00 p.m. ET
Spero Therapeutics, Inc. Contact: Sharon Klahre 857-242-1547 IR@sperotherapeutics.com
Nasdaq MarketSite Media Contact: Emily Pan (646) 441-5120 emily.pan@nasdaq.com
Feed Information: Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
Social Media: For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page: http://www.facebook.com/NASDAQ .
For photos from ceremonies and events, please visit our Instagram page: http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page: http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page: http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page: http://nasdaq.tumblr.com/
Webcast: A live stream of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos: To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.
About Spero Therapeutics, Inc. Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for MDR bacterial infections.
Spero is advancing SPR994, which is designed to be the first broad-spectrum oral antibiotic for use in adults to treat MDR Gram-negative infections.
Spero is also advancing its Potentiator Platform, which it believes will enable it to develop drugs that will expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. SPR741, Spero’s lead potentiator product candidate, is a clinical-stage, IV-administered agent that has been observed in in vitro studies to potentiate over two dozen existing antibiotics by expanding their activity against Gram-negative pathogens. SPR206, Spero’s preclinical potentiator product candidate, is also designed to have antibiotic activity as a single agent against certain MDR and extremely drug resistant (XDR) bacterial strains.
Spero is also developing SPR720, its novel oral therapy product candidate designed for the treatment of pulmonary non-tuberculous mycobacterial (NTM) infections.
For more information, please visit https://sperotherapeutics.com
About Nasdaq: Nasdaq (Nasdaq: NDAQ ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com
-NDAQA-
